Megakaryocyte pathology and bone marrow fibrosis: The lysyl oxidase connection

Blood

Volumn 120, Issue 9, 2012, Pages 1774-1781

  Papadantonakis, Nikolaos ^a,b   Matsuura, Shinobu ^a   Ravid, Katya ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPIONITRILE; ACETYLSALICYLIC ACID; ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ELASTIN; GS 6624; HYDROXYUREA; IMMUNOMODULATING AGENT; JANUS KINASE 2; LESTAURTINIB; OXIDOREDUCTASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; POMALIDOMIDE; PREDNISONE; PROTEIN LYSINE 6 OXIDASE; RETICULIN; RUXOLITINIB; THALIDOMIDE DERIVATIVE; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ANEMIA; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; DIARRHEA; DOWN SYNDROME; DRUG ERUPTION; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; EOSINOPHILIC LEUKEMIA; FEVER; FIBROBLAST; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MEGAKARYOBLAST; MEGAKARYOCYTE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NEUTROPENIA; NONHUMAN; PLOIDY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SPLEEN SIZE; STEM CELL TRANSPLANTATION; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

EID: 84865725060     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-402594     Document Type: Review

References (100)

1. Ravid K, Lu J, Zimmet JM, Jones MR. Roads to polyploidy: the megakaryocyte example. J Cell Physiol. 2002;190(1):7-20.
2. Geddis AE. Megakaryopoiesis. Semin Hematol. 2010;47(3):212-219.
3. Lion T, Haas OA. Acute megakaryocytic leukemia with the t(1;22)(p13;q13). Leuk Lymphoma. 1993;11(1):15-20.
4. Shimizu R, Engel JD, Yamamoto M. GATA1-related leukaemias. Nat Rev Cancer. 2008;8(4):279-287.
5. Crispino JD. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol. 2005;16(1):137-147.
6. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32(1):148-152.
7. Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood. 2009;113(12):2619-2628.
8. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110(3):512-524.
9. Harigae H, Xu G, Sugawara T, Ishikawa I, Toki T, Ito E. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood. 2004;103(8):3242-3243.
10. Tallman MS, Neuberg D, Bennett JM, et al. Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood. 2000;96(7):2405-2411.
11. Walters DK, Mercher T, Gu TL, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 2006;10(1):65-75.
12. Sheikha A. Fatal familial infantile myelofibrosis. J Pediatr Hematol Oncol. 2004;26(3):164-168.
13. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372-375.
14. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol. 2010;91(2):174-179.
15. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22(7):1299-1307.
16. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111(3):1686-1689.
17. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112(1):141-149.
18. Wang W, Schwemmers S, Hexner EO, Pahl HL. AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood. 2010;116(2):254-266.
19. Mercher T, Wernig G, Moore SA, et al. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. Blood. 2006;108(8):2770-2779.
20. Chim CS, Wan TS, Wong KY, Fung TK, Drexler HG, Wong KF. Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med. 2011;9(1):197.
21. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-1735.
22. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438.
23. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-761.
24. Dingli D, Schwager SM, Mesa RA, Li CY, Dewald GW, Tefferi A. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Cancer. 2006;106(9):1985-1989.
25. Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111(7):3383-3387.
26. Campbell PJ, Bareford D, Erber WN, et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27(18):2991-2999.
27. Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andreasson B. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011;86(2):148-155.
28. Hoffman R, Rondelli D. Biology and treatment of primary myelofibrosis. Hematology Am Soc Hematol Educ Program. 2007;2007:346-354.
29. Barosi G, Hoffman R. Idiopathic myelofibrosis. Semin Hematol. 2005;42(4):248-258.
30. Vannucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222-230.
31. Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood. 2008;111(4):1862-1865.
32. Rambaldi A, Barbui T, Barosi G. From palliation to epigenetic therapy in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2008;2008:83-91.
33. Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351-362.
34. Bauermeister DE. Quantitation of bone marrow reticulin: a normal range. Am J Clin Pathol. 1971;56(1):24-31.
35. Beckman EN, Brown AW Jr. Normal reticulin level in iliac bone marrow. Arch Pathol Lab Med. 1990;114(12):1241-1243.
36. Terui T, Niitsu Y, Mahara K, et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood. 1990;75(7):1540-1548.
37. Reilly JT, Barnett D, Dolan G, Forrest P, Eastham J, Smith A. Characterization of an acute micromegakaryocytic leukaemia: evidence for the pathogenesis of myelofibrosis. Br J Haematol. 1993;83(1):58-62.
38. Vannucchi AM, Bianchi L, Paoletti F, et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood. 2005;105(9):3493-3501.
39. Centurione L, Di Baldassarre A, Zingariello M, et al. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood. 2004;104(12):3573-3580.
40. Ponce CC, de Lourdes FCM, Ihara SS, Silva MR. The relationship of the active and latent forms of TGF-beta1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis [published online ahead of print December 27, 2011]. Med Oncol. doi:10.1007/s12032-011-0144-1.
41. Varricchio L, Mancini A, Migliaccio AR. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol. 2009; 2(3):315-334.
42. Le Bousse-Kerdiles MC, Fernandez-Delgado R, Smadja-Joffe F, et al. Abnormal splenic megakaryopoiesis in MPSV-induced myeloproliferative disease. Leuk Res. 1987;11(9):781-787.
43. Zhou W, Toombs CF, Zou T, Guo J, Robinson MO. Transgenic mice overexpressing human c-mpl ligand exhibit chronic thrombocytosis and display enhanced recovery from 5-fluorouracil or antiplatelet serum treatment. Blood. 1997;89(5):1551-1559.
44. Kakumitsu H, Kamezaki K, Shimoda K, et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. Leuk Res. 2005;29(7):761-769.
45. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009;114(18):3748-3756.
46. Frey BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MA. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol. 1998;160(2):691-699.
47. Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17(6):584-596.
48. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood. 2010;115(17):3589-3597.
49. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
50. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107(11):4274-4281.
51. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-1660.
52. Schmidt A, Blanchet O, Dib M, Basle MF, Ifrah N, Chappard D. Bone changes in myelofibrosis with myeloid metaplasia: a histomorphometric and microcomputed tomographic study. Eur J Haematol. 2007;78(6):500-509.
53. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
54. Malinge S, Ragu C, Della-Valle V, et al. Activating mutations in human acute megakaryoblastic leukemia. Blood. 2008;112(10):4220-4226.
55. Mercher T, Raffel GD, Moore SA, et al. The OTTMAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest. 2009;119(4):852-864.
56. Vannucchi AM, Bianchi L, Cellai C, et al. Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1(low) mice). Blood. 2001;97(10):3040-3050.
57. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood. 2002;100(4):1123-1132.
58. Kirsammer G, Jilani S, Liu H, et al. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood. 2008;111(2):767-775.
59. Barosi G, Lupo L, Rosti V. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice. Curr Hematol Malig Rep. 2012;7(1):50-56.
60. Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood. 1992;79(8):1931-1937.
61. Stein BL, Crispino JD, Moliterno AR. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr Opin Oncol. 2011;23(6):609-616.
62. Guglielmelli P, Barosi G, Rambaldi A, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069-2076.
63. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446-455.
64. Parikh SA, Kantarjian H, Schimmer A, et al. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010;10(4):285-289.
65. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807.
66. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2005;115(15):3109-3117.
67. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-798.
68. Hexner EO, Serdikoff C, Jan M, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008;111(12):5663-5671.
69. Santos FP, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood. 2010;115(6):1131-1136.
70. Crane E, List A. Immunomodulatory drugs. Cancer Invest. 2005;23(7):625-634.
71. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27(28):4760-4766.
72. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009; 27(27):4563-4569.
73. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003;88(4):660-672.
74. Bock O, Hoftmann J, Theophile K, et al. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. Am J Pathol. 2008;172(4):951-960.
75. Eliades A, Papadantonakis N, Bhupatiraju A, et al. Control of megakaryocyte expansion and bone marrow fibrosis by lysyl oxidase. J Biol Chem. 2011;286(31):27630-27638.
76. Bondareva A, Downey CM, Ayres F, et al. The lysyl oxidase inhibitor, beta-aminopropionitrile, diminishes the metastatic colonization potential of circulating breast cancer cells. PLoS One. 2009;4(5):e5620.
77. Barrow MV, Simpson CF, Miller EJ. Lathyrism: a review. Q Rev Biol. 1974;49(2):101-128.
78. Keiser HR, Sjoerdsma A. Studies on beta-aminopropionitrile in patients with scleroderma. Clin Pharmacol Ther. 1967;8(4):593-602.
79. Peacock EE Jr, Madden JW. Some studies on the effects of beta-aminopropionitrile in patients with injured flexor tendons. Surgery. 1969;66(1):215-223.
80. Peacock EE Jr. Pharmacologic control of surface scarring in human beings. Ann Surg. 1981;193(5):592-597.
81. Peacock EE, Madden JW. Administration of beta-aminopropionitrile to human beings with urethral strictures: a preliminary report. Am J Surg. 1978;136(5):600-605.
82. Peacock EE Jr. Biologic frontiers in the control of healing: Thomas G. Orr Memorial Lecture. Am J Surg. 1973;126(6):708-713.
83. Lucero HA, Ravid K, Grimsby JL, et al. Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells. J Biol Chem. 2008;283(35):24103-24117.
84. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol. 1998;16(7):387-398.
85. Gao S, Zhao Y, Kong L, et al. Cloning and characterization of the rat lysyl oxidase gene promoter: identification of core promoter elements and functional nuclear factor I-binding sites. J Biol Chem. 2007;282(35):25322- 25337.
86. Pez F, Dayan F, Durivault J, et al. The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res. 2011;71(5):1647-1657.
87. Green RS, Lieb ME, Weintraub AS, et al. Identification of lysyl oxidase and other platelet-derived growth factor-inducible genes in vascular smooth muscle cells by differential screening. Lab Invest. 1995;73(4):476-482.
88. Hong HH, Uzel MI, Duan C, Sheff MC, Trackman PC. Regulation of lysyl oxidase, collagen, and connective tissue growth factor by TGF-beta1 and detection in human gingiva. Lab Invest. 1999;79(12):1655-1667.
89. Siddikuzzaman Grace VM, Guruvayoorappan C. Lysyl oxidase: a potential target for cancer therapy. Inflammopharmacology. 2011;19(3):117-129.
90. Payne SL, Hendrix MJ, Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer: a prospect. J Cell Biochem. 2007;101(6):1338-1354.
91. Maki JM. Lysyl oxidases in mammalian development and certain pathological conditions. Histol Histopathol. 2009;24(5):651-660.
92. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009-1017.
93. Raslova H, Kauffmann A, Sekkai D, et al. Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood. 2007;109(8):3225-3234.
94. Piersma SR, Broxterman HJ, Kapci M, et al. Proteomics of the TRAP-induced platelet releasate. J Proteomics. 2009;72(1):91-109.
95. Pischon N, Maki JM, Weisshaupt P, et al. Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype. Calcif Tissue Int. 2009;85(2):119-126.
96. Bignon M, Pichol-Thievend C, Hardouin J, et al. Lysyl oxidase-like protein-2 regulates sprouting angiogenesis and type IV collagen assembly in the endothelial basement membrane. Blood. 2011;118(14):3979-3989.
97. Villeval JL, Cohen-Solal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood. 1997;90(11):4369-4383.
98. Gu TL, Mercher T, Tyner JW, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood. 2007;110(1):323-333.
99. Toki T, Katsuoka F, Kanezaki R, et al. Transgenic expression of BACH1 transcription factor results in megakaryocytic impairment. Blood. 2005;105(8):3100-3108.
100. Kaufmann KB, Grunder A, Hadlich T, et al. A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J Exp Med. 2012;209(1):35-50.